Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCX 546
说明： AMPA potentiator
化学名： (2,3-Dihydro-1,4-benzodioxin-6-yl)-1-piperidinylmethanone
纯度： ≥99% (HPLC)
生物活性 for CX 546
CX 546 is an AMPA receptor potentiator. Binds specifically to the agonist bound non-desensitized receptor, most likely destabilizing the desensitized receptor conformation. Enhances cognitive function in rats. Neuroprotective in mice undergoing repeat ketamine anesthesia.
技术数据 for CX 546
| 分子量 | 247.29 |
| 公式 | C14H17NO3 |
| 储存 | Store at +4°C |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 215923-54-9 |
| PubChem ID | 2890 |
| InChI Key | LJUNPHMOGNFFOS-UHFFFAOYSA-N |
| Smiles | O=C(N3CCCCC3)C2=CC1=C(C=C2)OCCO1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for CX 546
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 24.73 | 100 | |
| ethanol | 24.73 | 100 |
制备储备液 for CX 546
以下数据基于产品分子量 247.29。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 4.04 mL | 20.22 mL | 40.44 mL |
| 5 mM | 0.81 mL | 4.04 mL | 8.09 mL |
| 10 mM | 0.4 mL | 2.02 mL | 4.04 mL |
| 50 mM | 0.08 mL | 0.4 mL | 0.81 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for CX 546
参考文献 for CX 546
参考文献是支持产品生物活性的出版物。
Nagararjan et al (2001) Mechanism and impact of allosteric AMPA receptor modulation by the ampakine TM CX546. Neuropharmacology. 41 650 PMID: 11640919
O'Neill et al (2004) AMPA receptor potentiators for the treatment of CNS disorders. Curr.Drug Targets CNS Neurol.Disord. 3 181 PMID: 15180479
Shimazaki et al (2007) Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats. Eur.J.Pharmacol. 575 94 PMID: 17727837
Huang et al (2016) Post-anesthesia AMPA receptor potentiation prevents anesthesia-induced learning and synaptic deficits. Sci.Transl.Med. 8 ra85 PMID: 27334260
If you know of a relevant reference for CX 546, please let us know.
按产品操作查看相关产品
关键词: CX 546, CX 546 supplier, AMPA, receptor, potentiator, Glutamate, Receptors, iGluR, Ionotropic, CX546, 2980, Tocris Bioscience
CX 546 的评论
目前没有该产品的评论。 Be the first to review CX 546 and earn rewards!
Have you used CX 546?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.